Ifeanyichukwu Ifechidere: Which Coagulation Factors Are Not Involved in Bleeding?
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
Do You Know Which Coagulation Factors Are Not Involved in Bleeding?
This is one of those questions that separates surface-level understanding from true clinical insight.
Most people assume:
If a coagulation factor is abnormal, bleeding risk must increase.
But that’s not always true.
Let’s break it down:
There are specific factors in the coagulation cascade that, when deficient, do NOT typically cause bleeding:
- Factor XII
- Prekallikrein
- High Molecular Weight Kininogen (HMWK)
Why does this matter?
These factors belong to the contact activation pathway (intrinsic pathway in vitro).
They are essential for laboratory clotting tests (like APTT)
But not essential for in vivo haemostasis
Clinical implication:
A patient may present with:
- Markedly prolonged APTT
- No bleeding history
And the reason could be a deficiency in one of these factors.
This is where many get it wrong:
- Unnecessary delays in procedures
- Incorrect clinical concern
- Misinterpretation of lab results
Key takeaway:
- Not every abnormal coagulation result equals bleeding risk.
- Understanding which factors matter clinically is what transforms you from someone who reports results – to someone who interprets with authority.
Want to build real confidence in coagulation interpretation?
I’ve created a fundamental coagulation course built around 15 real-life case studies – designed for:
- Students
- Interns
- Practicing professionals
This is not theory – heavy learning.
It’s focused on helping you:
- Recognise patterns instantly
- Avoid common interpretation mistakes
- Think like a specialist in real lab scenarios
Because confidence in coagulation doesn’t come from memorising pathways – it comes from seeing and solving real cases.”
More posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Jul 3, 2026, 05:50Jacopo Parizzi: Roche’s Non-Malignant Hematology Team Is Looking Ahead to 2027
-
Jul 3, 2026, 05:25Brian A Beh: A New Approach from The George Institute for Global Health Could Transform Stroke Care Before Hospital Arrival
-
Jul 3, 2026, 05:22Deirdre Finnigan: New Insights into Red Blood Cell Biomechanics in Cancer-Associated Anemia
-
Jul 3, 2026, 05:15Danielle Boyle: Collaboration Across Borders Is Helping Shape the Future of ITP Care
-
Jul 3, 2026, 05:05Claire McIvor: One Year at the Stroke Association and Grateful for a Workplace That Made It Possible
-
Jul 2, 2026, 23:11Michael Makris: Join The Cancer Associated Thrombosis Workshop at ISTH 2026
-
Jul 2, 2026, 21:54Rob Maloney: Rare Disease Requires Relational Care
-
Jul 2, 2026, 21:53Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy
-
Jul 2, 2026, 21:52Emina Curic: Improving the Understanding of Factor V Leiden in Everyday Clinical Practice